GWS
ESPR icon

Glassman Wealth Services’s Esperion Therapeutics ESPR Stock Holding History

Glassman Wealth Services’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-270
Closed -$1K – 1724
2021
Q4 		$1K Buy
+270
New +$2.16K ﹤0.01% 1361
2019
Q4 		– Sell
-7
Closed – – 1257
2019
Q3 		$0 Buy
+7
New +$277 ﹤0.01% 1130

Other funds holding ESPR

Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
Deep Track Capital
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Bellevue Group
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
ACM
Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Paradigm Biocapital Advisors
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Glassman Wealth Services's ESPR Position: Q1 2022 in Review

Glassman Wealth Services sold out of Esperion Therapeutics (ESPR) in Q1 2022, closing a stake of 270 shares — an estimated $1K sold.

Glassman Wealth Services first reported a position in ESPR in Q3 2019 and held it in 2 quarters. The position peaked at $1K in Q4 2021. 132 funds tracked by Wall St. Rank hold ESPR as of Q1 2022.

  • Glassman Wealth Services reported no remaining Esperion Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Glassman Wealth Services sold 270 Esperion Therapeutics shares in Q1 2022, an estimated $1K.
  • Glassman Wealth Services first reported a position in Esperion Therapeutics in Q3 2019 and held it in 2 quarters.
  • Glassman Wealth Services's Esperion Therapeutics position peaked at $1K in Q4 2021.
  • 132 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2022.

Based on Glassman Wealth Services's 13F filing for Q1 2022, filed 14 Apr 2022.